ZTS:NYSE
Zoetis Inc
USD 82,57
arrow_upward
+0,13%(+0,11) 1D
USD 82,69
arrow_upward
+0,15% (+0,12)bedtimeAfter hours
Closed: 11 Nov., 16:00:04 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZTS...
Open
USD 81,49
High
USD 82,64
Low
USD 80,79
Mkt. cap
33,55 mjd
Avg. vol.
4,53 m
Volume
4,45 m
Dividend
2,57%
Quarterly dividend
USD 0,53
Ex-dividend date
30 Okt. 2026
P/E ratio
14,02
52-wk high
USD 132,49
52-wk low
USD 68,77
EPS
USD 5,89
Beta
0,67
Shares outstanding
406,32 m
No. of employees
14 k
Open
USD 81,49
High
USD 82,64
Low
USD 80,79
Mkt. cap
33,55 mjd
Avg. vol.
4,53 m
Volume
4,45 m
Dividend
2,57%
Quarterly dividend
USD 0,53
Ex-dividend date
30 Okt. 2026
P/E ratio
14,02
52-wk high
USD 132,49
52-wk low
USD 68,77
EPS
USD 5,89
Beta
0,67
Shares outstanding
406,32 m
No. of employees
14 k
News stories
From web sources and news partners
Yahoo Finance
·
14 uur gelede
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
Barchart.com
·
16 uur gelede
What Are Wall Street Analysts' Target Price for Zoetis Stock?
Trefis
·
1 dag gelede
Should You Buy Zoetis Stock At This Price?
Yahoo Finance
·
1 dag gelede
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.
In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14,5 k
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, Verenigde State van Amerika
SectorHealth Care
IndustryPharmaceutical industry
Websitezoetis.com